These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 9844789

  • 1. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease.
    Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, Mouradian MM, Chase TN.
    Clin Neuropharmacol; 1998; 21(6):339-43. PubMed ID: 9844789
    [Abstract] [Full Text] [Related]

  • 2. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
    Goulet M, Madras BK.
    J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
    [Abstract] [Full Text] [Related]

  • 3. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
    Temlett JA, Quinn NP, Jenner PG, Marsden CD, Pourcher E, Bonnet AM, Agid Y, Markstein R, Lataste X.
    Mov Disord; 1989 Feb; 4(3):261-5. PubMed ID: 2571082
    [Abstract] [Full Text] [Related]

  • 4. Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease.
    Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):338-44. PubMed ID: 11160615
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Central dopaminergic D1 agonists and treatment of Parkinson disease].
    Soubrouillard C, Lombardo C, Rascol O, Bruguerolle B, Blin O.
    Therapie; 1997 Nov; 52(6):527-34. PubMed ID: 9734104
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [Abstract] [Full Text] [Related]

  • 11. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.
    George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB.
    Schizophr Res; 2007 Jul; 93(1-3):42-50. PubMed ID: 17467956
    [Abstract] [Full Text] [Related]

  • 12. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia.
    Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, Nahas Z, Kozel FA, Kose S, Knable M, Fernandes P, Nichols DE, Mailman RB, George MS.
    Schizophr Res; 2007 Aug; 94(1-3):332-41. PubMed ID: 17596915
    [Abstract] [Full Text] [Related]

  • 13. Dihydrexidine--the first full dopamine D1 receptor agonist.
    Salmi P, Isacson R, Kull B.
    CNS Drug Rev; 2004 Aug; 10(3):230-42. PubMed ID: 15492773
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder.
    Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, Harvey PD, Girgis RR, Hazlett EA, Mailman RB, Abi-Dargham A, Lieberman JA, Siever LJ.
    Neuropsychopharmacology; 2015 Jan; 40(2):446-53. PubMed ID: 25074637
    [Abstract] [Full Text] [Related]

  • 17. Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.
    Emre M, Rinne UK, Rascol A, Lees A, Agid Y, Lataste X.
    Mov Disord; 1992 Jan; 7(3):239-43. PubMed ID: 1535688
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.